ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Addex Therapeutics Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026
$2.89+0.13 (+4.71%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 148M shares
Institutional holders
2
1 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Timothy Mark Dyer | 19,165,714 | 9.01% | 13D (active) amendment | Sep 2, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ADXN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| UBS Group AG | 47 | 0.00% | $268 | New | 0.00% |
| SBI Securities Co., Ltd. | 1 | 0.00% | $6 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2 | 0M | 0.0% | 1 / 0 | 0 / 3 | 0M | 0M |
| Q1 2026 | 4 | 0M | 0.0% | 0 / 1 | 0 / 1 | 0M | 0M |
| Q4 2025 | 5 | 0M | 0.0% | 1 / 1 | 2 / 0 | 0M | 0M |
| Q3 2025 | 4 | 0M | 0.0% | 1 / 0 | 0 / 2 | 0M | 0M |
| Q2 2025 | 5 | 0M | 0.0% | 1 / 0 | 1 / 1 | 0M | 0M |
| Q1 2025 | 5 | 0M | 0.0% | 0 / 1 | 3 / 0 | 0M | 0M |
| Q4 2024 | 5 | 0M | 0.0% | 3 / 2 | 0 / 1 | 0M | 0M |
| Q3 2024 | 3 | 0M | 0.0% | 1 / 1 | 1 / 0 | 0M | 0M |
| Q2 2024 | 2 | 0M | 0.0% | 1 / 1 | 0 / 0 | 0M | 0M |
| Q1 2024 | 1 | 0M | 0.0% | 1 / 0 | 0 / 3 | 0M | 0M |
| Q4 2023 | 3 | 0M | 0.1% | 3 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Roger Mills | CHIEF MEDICAL OFFICER, Director | 785,976 | 0.53% | Sep 4, 2026 |
| Timothy Mark Dyer | CHIEF EXECUTIVE OFFICER, Director | 435,192 | 0.29% | Sep 4, 2026 |
| Mikhail Kalinichev | HEAD OF TRANSLATIONAL SCIENCE | 0 | – | Sep 4, 2026 |
| Lenaic Nathanael Teyssedou | PRINCIPAL ACCOUNTING OFFICER | – | – | Sep 4, 2026 |
| Jason Raleigh Nunn | Director | 219,561 | 0.15% | Sep 4, 2026 |
| Vincent Michael Lawton | Director | 2,507,987 | 1.70% | Sep 4, 2026 |
| Raymond George Hill | Director | 0 | – | Sep 4, 2026 |
| Isaac Manke | Director | 219,561 | 0.15% | Sep 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jason Raleigh Nunn Director | Sep 2, 2026 | Award | +219,561 | – | – | 219,561 |
| Jason Raleigh Nunn Director | Sep 2, 2026 | Returned to company | −219,561 | – | – | 0 |
| Timothy Mark Dyer CHIEF EXECUTIVE OFFICER, Director | Sep 2, 2026 | Returned to company | −16,413,787 | – | – | 435,192 |
| Timothy Mark Dyer CHIEF EXECUTIVE OFFICER, Director | Sep 2, 2026 | Award | +16,413,787 | – | – | 16,848,979 |
| Mikhail Kalinichev HEAD OF TRANSLATIONAL SCIENCE | Sep 2, 2026 | Returned to company | −306,765 | – | – | 0 |
| Mikhail Kalinichev HEAD OF TRANSLATIONAL SCIENCE | Sep 2, 2026 | Award | +306,765 | – | – | 306,765 |
| Raymond George Hill Director | Sep 2, 2026 | Returned to company | −1,365,532 | – | – | 0 |
| Raymond George Hill Director | Sep 2, 2026 | Award | +1,365,532 | – | – | 1,365,532 |
| Roger Mills CHIEF MEDICAL OFFICER, Director | Sep 2, 2026 | Award | +392,837 | – | – | 785,976 |
| Roger Mills CHIEF MEDICAL OFFICER, Director | Sep 2, 2026 | Returned to company | −392,837 | – | – | 393,139 |
| Vincent Michael Lawton Director | Sep 2, 2026 | Award | +2,507,487 | – | – | 2,507,987 |
| Vincent Michael Lawton Director | Sep 2, 2026 | Returned to company | −2,507,487 | – | – | 500 |
| Isaac Manke Director | Sep 2, 2026 | Award | +219,561 | – | – | 219,561 |
| Isaac Manke Director | Sep 2, 2026 | Returned to company | −219,561 | – | – | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.